Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis

Ioanna Minopoulou¹, Artur Wilhelm², Fredrik Albach¹, Arnd Kleyer¹, Edgar Wiebe¹, Simon Schallenberg³, Anja Fleischmann¹, Mareike Frick⁴, Frederik Damm⁴, Julia Gogolok⁴, Sebastian Serve⁴, Benjamin Nick Locher⁴, Dominic Borie⁵, Vincent Casteleyn¹, Robert Biesen¹, Thomas Dörner², Tobias Alexander², Jan Zernicke¹, Kamran Movassaghi⁴, Marie Luise Hütter-Krönke⁶, Eva Schrezenmeier⁷, Adrian Schreiber⁸, Udo Schneider¹, Lars Bullinger⁹, Gerhard Krönke¹⁰, Olaf Penack⁴, David Simon¹¹

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.
³ Institute of Pathology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
⁴ Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
⁵ Kyverna Therapeutics, Emeryville, CA, USA.
⁶ Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany.
⁷ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany.
⁸ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany.
⁹ Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany; Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
¹⁰ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany; Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
¹¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. Electronic address: david.simon@charite.de.

PMID: 39893102
DOI: 10.1016/j.ard.2025.01.008

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis

Ioanna Minopoulou et al. Ann Rheum Dis. 2025 Mar.

. 2025 Mar;84(3):e4-e7.

doi: 10.1016/j.ard.2025.01.008. Epub 2025 Jan 31.

Authors

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.
³ Institute of Pathology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.
⁴ Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
⁵ Kyverna Therapeutics, Emeryville, CA, USA.
⁶ Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany.
⁷ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany.
⁸ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany.
⁹ Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany; Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
¹⁰ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany; Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
¹¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. Electronic address: david.simon@charite.de.

PMID: 39893102
DOI: 10.1016/j.ard.2025.01.008

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests IM received speaker honoraria from AbbVie, Novartis. DS has served on scientific advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Lilly, Novartis, and UCB and received speaker honoraria from AbbVie, Alfasigma, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, and UCB. AK has served on scientific advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Lilly, Novartis, and UCB and received speaker honoraria from AbbVie, Alfasigma, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, and UCB. TD received honoraria for scientific advice by AbelZeta, BMS, J&J, Novartis, and Roche/Genentech. DB is an employee and shareholder of Kyverna Therapeutics. OP has received honoraria or travel support from Alexion, Gilead, Jazz, MSD, Neovii, Novartis, Pfizer, and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Apogepha, Alexion, Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Orca Bio, Priothera, Sanofi, Shionogi, and SOBI.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis

Affiliations

Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis

Authors

Affiliations

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources